{"id":"W4327850169","doi":"10.1177/17588359231157633","title":"A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba; Western University; Centre Hospitalier de l’Université de Montréal; University of Calgary; University of Manitoba; Princess Margaret Cancer Centre; University of Toronto; University of British Columbia","funders":"Merck Canada; Eisai Canada; Eisai; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Endometrial cancer; Oncology; Internal medicine; Microsatellite instability; Lenvatinib; Metastatic breast cancer; Cancer; Breast cancer; Immunotherapy; Thyroid cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002424564,0.0008131818,0.006188947,0.001961439,0.00005250243,0.00001646138,0.0005130662,0.0009480678,0.00325245],"category_scores_gemma":[0.002846925,0.0005517507,0.0008190706,0.005478582,0.0003505592,0.000149399,0.0002132534,0.002115152,0.0001552943],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002121485,"about_ca_system_score_gemma":0.002730507,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003984718,"about_ca_topic_score_gemma":0.0008242623,"domain_scores_codex":[0.9926113,0.00119448,0.002920537,0.0009824558,0.001230789,0.001060458],"domain_scores_gemma":[0.9931798,0.004961435,0.0008243233,0.0004821986,0.00008647879,0.0004657412],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007637959,0.0007910192,0.0002560059,0.008058363,0.0007559221,0.001805476,0.0001203861,0.000002875146,0.000001349543,0.00002874937,0.00002080022,0.9873953],"study_design_scores_gemma":[0.01963439,0.00186503,0.0001312823,0.02898125,0.002224282,0.0002023429,0.0001281972,0.0000777731,0.000006630434,0.0005667809,0.94561,0.0005720867],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000724576,0.9924265,0.00002711344,0.0004800706,0.002253909,0.002672379,0.00004175223,0.0001367751,0.001889047],"genre_scores_gemma":[0.000579272,0.9952001,0.0001894955,0.0003133385,0.0009327264,0.002135245,0.0001694615,0.0001435078,0.0003368521],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9868231,"threshold_uncertainty_score":0.9996934,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07530303729759415,"score_gpt":0.4436830654516157,"score_spread":0.3683800281540216,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}